These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 1879046)
21. 1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review. Carter SK; Schabel FM; Broder LE; Johnston TP Adv Cancer Res; 1972; 16():273-332. PubMed ID: 4563045 [No Abstract] [Full Text] [Related]
22. Nitrosoureas lomustine, carmustine and fotemustine induced hepatotoxic perturbations in rats: biochemical, morphological and flow cytometry studies. Laquerriere A; Raguenez-Viotte G; Paraire M; Bizzari JP; Paresy M; Fillastre JP; Hemet J Eur J Cancer; 1991; 27(5):630-8. PubMed ID: 1828975 [TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of new nitrosoureas on Yoshida sarcoma ascites cells implanted into the colon wall of rats. Habs M; Reinbold H; Eisenbrand G; Bhide S; Goga-Ionescu S; Schmähl D J Cancer Res Clin Oncol; 1981; 101(3):285-302. PubMed ID: 7309781 [TBL] [Abstract][Full Text] [Related]
24. Some new congeners of the anticancer agent 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Synthesis of bifunctional analogs and water soluble derivatives and preliminary evaluation of their chemotherapeutic potential. Eisenbrand G; Fiebig HH; Zeller WJ Z Krebsforsch Klin Onkol Cancer Res Clin Oncol; 1976 Aug; 86(3):279-86. PubMed ID: 136102 [TBL] [Abstract][Full Text] [Related]
25. Hepatic intra-arterial infusion of fotemustine: pharmacokinetics. Fety R; Lucas C; Solere P; Cour V; Vignoud J Cancer Chemother Pharmacol; 1992; 31(2):118-22. PubMed ID: 1451232 [TBL] [Abstract][Full Text] [Related]
26. Phase I pharmacokinetics study of high-dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas. Tranchand B; Lucas C; Biron P; Giroux B; Gordon B; Richards R; Solere P; Roux N; Evene E; Mornex F Cancer Chemother Pharmacol; 1993; 32(1):46-52. PubMed ID: 8462123 [TBL] [Abstract][Full Text] [Related]
27. [Interspecies comparison of pharmacokinetic parameters of fotemustine (nitrosourea S 10036): mice, rats, monkeys, dogs and man]. Lucas C; Ings B; Gray AJ; Deloffre P; Lokiec F; Campbell B; Beerblock K Bull Cancer; 1989; 76(8):863-5. PubMed ID: 2515897 [No Abstract] [Full Text] [Related]
28. Fotemustine for the treatment of melanoma. Quéreux G; Dréno B Expert Opin Pharmacother; 2011 Dec; 12(18):2891-904. PubMed ID: 22077794 [TBL] [Abstract][Full Text] [Related]
29. Improved antitumor effect of the nitrosourea drugs tauromustine (TCNU) and carmustine (BCNU) on a rat liver adenocarcinoma after hepatic arterial administration with degradable starch microspheres. Roos G; el Hag IA; Teder H; Stenram U Anticancer Res; 1991; 11(1):13-6. PubMed ID: 2018346 [TBL] [Abstract][Full Text] [Related]
30. Disposition, pharmacokinetics, and metabolism of 14C-fotemustine in cancer patients. Ings RM; Gray AJ; Taylor AR; Gordon BH; Breen M; Hiley M; Brownsill R; Marchant N; Richards R; Wallace D Eur J Cancer; 1990; 26(7):838-42. PubMed ID: 2145908 [TBL] [Abstract][Full Text] [Related]
31. Phase II and pharmacokinetic study of fotemustine in inoperable colorectal cancer. Rougier P; Chabot GG; Bonneterre J; Tigaud JM; Lucas C; Baud M; Bérille J; Gouyette A Eur J Cancer; 1993; 29A(2):288-9. PubMed ID: 8422301 [No Abstract] [Full Text] [Related]
32. Relationship of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) pharmacokinetics of uptake, distribution, and tissue/plasma partitioning in rat organs and intracerebral tumors. Levin VA; Kabra PA; Freeman-Dove MA Cancer Chemother Pharmacol; 1978; 1(4):233-42. PubMed ID: 750110 [TBL] [Abstract][Full Text] [Related]
34. [On the therapy of lymphogranuloma. CCNU (1(2-chlorethyl)-3-cyclohexyl-1-nitrosourea) and BCNU (1,3-bis(2-chlorethyl)-1-nitrosourea) as well as BCNU combinations in Hodgkin's lymphogranuloma, stage 3 and 4]. Brunner KW; Maurice P; Sonntag RW Schweiz Med Wochenschr; 1972 Oct; 102(43):1546-51. PubMed ID: 4647016 [No Abstract] [Full Text] [Related]
35. Effect of 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea on experimental tumors. Akaike Y; Arai Y; Taguchi H; Satoh H Gan; 1982 Jun; 73(3):480-7. PubMed ID: 7129012 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of nitrosoureas: comparison of 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) after oral and intravenous administration to rats. Russo RG; Cattaneo MT; Bartosek I Tumori; 1984 Dec; 70(6):499-502. PubMed ID: 6531792 [TBL] [Abstract][Full Text] [Related]
37. Effects of the new nitrosourea derivative, fotemustine, on the glutathione reductase activity in rat tissues in vivo and in isolated rat hepatocytes. Boutin JA; Norbeck K; Moldeus P; Genton A; Paraire M; Bizzari JP; Lavielle G; Cudennec CA Eur J Cancer Clin Oncol; 1989 Sep; 25(9):1311-6. PubMed ID: 2806354 [TBL] [Abstract][Full Text] [Related]
38. Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone. Kostenuik PJ; Singh G; Suyama KL; Orr FW Clin Exp Metastasis; 1992 Nov; 10(6):411-8. PubMed ID: 1451351 [TBL] [Abstract][Full Text] [Related]
39. A new method for the measurement of nitrosoureas in plasma: an h.p.l.c. procedure for the measurement of fotemustine kinetics. Gordon BH; Richards RP; Hiley MP; Gray AJ; Ings RM; Campbell DB Xenobiotica; 1989 Mar; 19(3):329-39. PubMed ID: 2665327 [TBL] [Abstract][Full Text] [Related]
40. Synergistic efficacy of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a human colon cancer xenograft completely resistant to BCNU alone. Gerson SL; Zborowska E; Norton K; Gordon NH; Willson JK Biochem Pharmacol; 1993 Jan; 45(2):483-91. PubMed ID: 8435098 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]